PARP1 and neoplasm: Beyond PARP inhibition, ATR inhibitors—such as ceralasertib and elimusertib—act by inducing replication fork collapse and accumulation of double-strand breaks during S-phase, which activates innate immune pathways and enhances tumor sensitivity to both radiotherapy and immunotherapy [122,123].